Name (Synonyms) | Correlation | |
---|---|---|
drug309 | Five-days oseltamivir Wiki | 1.00 |
drug311 | Fixed-duration higher dose Hydrocortisone Wiki | 1.00 |
drug491 | Macrolide administered for 3-5 days Wiki | 1.00 |
drug831 | Ten-days oseltamivir Wiki | 1.00 |
drug366 | Hydroxychloroquine + lopinavir/ritonavir Wiki | 1.00 |
drug518 | Moxifloxacin or Levofloxacin Wiki | 1.00 |
drug492 | Macrolide administered for up to 14 days Wiki | 1.00 |
drug310 | Fixed-duration Hydrocortisone Wiki | 1.00 |
drug433 | Interferon-β1a Wiki | 1.00 |
drug747 | Shock-dependent hydrocortisone Wiki | 1.00 |
drug179 | Ceftriaxone Wiki | 1.00 |
drug45 | Amoxicillin-clavulanate Wiki | 1.00 |
drug615 | Piperacillin-tazobactam Wiki | 1.00 |
drug732 | Sarilumab Wiki | 0.41 |
drug46 | Anakinra Wiki | 0.38 |
drug478 | Lopinavir/ritonavir Wiki | 0.32 |
drug854 | Tocilizumab Wiki | 0.25 |
drug360 | Hydroxychloroquine Wiki | 0.13 |
There is one clinical trial.
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome ofon patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic resulting in critical illness. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19.
Description: Primary end-point for patients with suspected or proven COVID-19 pandemic infection
Measure: Days alive and outside of ICU Time: Day 21Description: EQ5D-5L and WHODAS 2.0 (not completed in all regions)
Measure: Health-related Quality of life assessment Time: 6 monthsDescription: Characterised as home, rehabilitation hospital, nursing home or long-term care facility, or another acute hospital
Measure: Destination at time of hospital discharge Time: Free text Day 90Description: Antibiotic Domain specific outcome
Measure: Occurrence of multi-resistant organism colonisation/infection Time: Day 90, censored at hospital dischargeDescription: Antibiotic Domain specific outcome
Measure: Occurrence clostridium difficile Time: Day 90, censored at hospital dischargeDescription: Macrolide Duration domain specific outcome, and COVID-19 Antiviral Domain specific outcome.
Measure: Occurrence of serious ventricular arrhythmia (including ventricular fibrillation) or sudden unexpected death Time: Day 90, censored at hospital dischargeDescription: Antiviral Domain specific outcome. Only required at selected sites.
Measure: Change from baseline influenza virus levels in upper and lower respiratory tract specimens Time: Day 3, up to Day 7Description: COVID-19 Antiviral Domain and COVID-19 Immune Modulation Domain specific endpoint
Measure: Serial detection of SARS-CoV-2 in upper or lower respiratory tract specimens (using only specimens collected for routine clinical testing) Time: Day 90, censored at hospital discharge